Drug Shortage Report for CIPROFLOXACIN INTRAVENOUS INFUSION BP
| Report ID | 236750 |
| Drug Identification Number | 02304759 |
| Brand name | CIPROFLOXACIN INTRAVENOUS INFUSION BP |
| Common or Proper name | CIPROFLOXACIN 400MG 200ML |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | CIPROFLOXACIN |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10LIIF |
| ATC code | J01MA |
| ATC description | QUINOLONE ANTIBACTERIALS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-10-28 |
| Actual start date | |
| Estimated end date | 2024-12-31 |
| Actual end date | 2024-09-30 |
| Shortage status | Avoided shortage |
| Updated date | 2024-09-30 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4600 RUE ARMAND-FRAPPIER SAINT-HUBERT, QUEBEC CANADA J3Z 1G5 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2024-09-30 | French | Compare |
| v3 | 2024-09-30 | English | Compare |
| v2 | 2024-09-05 | French | Compare |
| v1 | 2024-09-05 | English | Compare |
Showing 1 to 4 of 4